These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37282500)

  • 1. Plain language summary of results from ORION-10 and ORION-11: two studies to learn how well inclisiran works in people with high cholesterol.
    Ray KK; Wright RS
    Future Cardiol; 2023 Mar; 19(4):175-184. PubMed ID: 37282500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
    Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
    Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
    Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
    Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
    S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
    Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
    Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
    N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
    Ray KK; Raal FJ; Kallend DG; Jaros MJ; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Lawrence D; Friedman A; Garcia Conde L; Wright RS;
    Eur Heart J; 2023 Jan; 44(2):129-138. PubMed ID: 36331326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18.
    Huo Y; Lesogor A; Lee CW; Chiang CE; Mena-Madrazo J; Poh KK; Jeong MH; Maheux P; Zhang M; Wei S; Han Y; Li Y
    JACC Asia; 2024 Feb; 4(2):123-134. PubMed ID: 38371290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on inclisiran for the treatment of elevated LDL cholesterol.
    Barkas F; Ray K
    Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary.
    Vohra LI; Rizwan K; Saeed E; Hamza MSA; Ochani S
    Egypt Heart J; 2023 Jul; 75(1):60. PubMed ID: 37439881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.
    Landmesser U; Koenig W; Leiter LA; Raal FJ; Ray KK; Wright RS; Han J; Conde LG; Schwartz GG
    Atherosclerosis; 2023 Dec; 386():117354. PubMed ID: 38016401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
    Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
    Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
    Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP
    JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.